Personalis (NASDAQ:PSNL) Announces Earnings Results

Personalis (NASDAQ:PSNL) posted its earnings results on Thursday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06), FiscalAI reports. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.49 million.

Here are the key takeaways from Personalis’ conference call:

• Personalis reported strong clinical volume momentum with 7,800 NeXT Personal tests in Q1 (26% sequential, 258% YoY), surpassed >1,000 ordering physicians in the quarter, and reconfirmed a 2026 clinical volume target of 43,000–45,000 tests.
• Q1 revenue was $15.5M (down ~25% YoY) and gross margin compressed to 1.8% due to unreimbursed scaling; net loss widened to $30M and full-year net loss is guided to about $105M with ~$100M expected cash usage despite a $233M cash balance.
• Reimbursement and clinical evidence progress: Medicare coverage for breast and lung surveillance is live, MolDX submissions are pending for neoadjuvant breast and pan?cancer IO, and presented data (NEOPRISM?CRC, DARWIN?2, 10k real?world cohort) highlighted high negative predictive value and the value of ultrasensitivity.
• Biopharma MRD momentum and backlog are growing: Q1 biopharma MRD revenue was $3.1M with management targeting $20M–$21M for the full year, expecting most MRD revenue to ramp in H2 as several large trials commence.

Personalis Stock Down 0.2%

NASDAQ:PSNL traded down $0.01 during trading hours on Friday, reaching $5.98. 2,726,526 shares of the stock were exchanged, compared to its average volume of 1,603,522. Personalis has a twelve month low of $3.84 and a twelve month high of $11.50. The business has a 50-day moving average of $6.93 and a two-hundred day moving average of $8.23. The company has a market capitalization of $625.97 million, a price-to-earnings ratio of -6.57 and a beta of 1.96.

Analyst Ratings Changes

Several analysts have recently commented on PSNL shares. Needham & Company LLC lifted their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. BTIG Research upped their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Finally, Morgan Stanley lowered their price target on Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Personalis presently has an average rating of “Moderate Buy” and an average target price of $11.50.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently modified their holdings of the company. Deutsche Bank AG boosted its holdings in Personalis by 4.5% during the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after acquiring an additional 1,655 shares during the period. Royal Bank of Canada increased its stake in Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the period. Howland Capital Management LLC lifted its position in shares of Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after purchasing an additional 2,500 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Personalis by 184.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock valued at $44,000 after purchasing an additional 3,592 shares during the period. Finally, Intech Investment Management LLC boosted its stake in shares of Personalis by 23.4% in the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after purchasing an additional 3,851 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.